互动和学习经验对公众对痴呆症的耻辱的作用:一项观察性跨部门研究
Taiji Noguchi1,2, Takeshi Nakagawa1, Ayane Komatsu1
1Department of Social Science, Research Institute, National Center for Geriatrics and Gerontology, Japan.
Dementia (London, England)
|October 19, 2023
概括
与痴呆症患者互动和了解他们显著减少了公众的耻辱,包括个人回避和对歧视的恐惧. 这些经验是克服与痴呆相关的社会耻辱的关键.
科学领域:
- 社会心理学 社会心理学
- 公共卫生 公共卫生
- 老年学是一门学科.
背景情况:
- 痴呆症的耻辱是一个重大的全球性挑战.
- 接触和教育是减少公众耻辱的潜在策略,但证据有限.
- 这项研究调查了与痴呆症相关的公共耻辱的调节因素,特别是互动和教育.
研究的目的:
- 检查直接互动和教育经验对公众对痴呆症的耻辱的影响.
- 评估不同级别的接触 (交谈,共同生活) 如何影响耻辱领域.
- 确定了解痴呆症对公众态度的影响.
主要方法:
- 在日本对710名成年人 (20-69岁) 进行了基于网络的横截面调查.
- 使用多维尺度评估公共耻辱 (个人回避,对标签的恐惧,以人为中心,对歧视的恐惧).
- 基于互动经验 (没有,谈话/活动,共同生活) 和学习经验 (是/不是) 的耻辱评分进行比较,控制人口统计.
主要成果:
- 互动经验 (谈话/活动,共同生活) 与减少个人回避和对歧视的恐惧有关.
- 学习经验与较低的个人回避和以人为中心的增加有关.
- 特定的耻辱领域,包括对标签的恐惧,因互动而显著减少.
结论:
- 促进与痴呆症患者的互动对于减少公众耻辱至关重要.
- 关于痴呆症的教育举措可以积极影响公众的看法并减少耻辱感.
- 这些发现支持有针对性的干预措施,以增加接触和知识,以打击痴呆症的耻辱感.
相关概念视频
01:04Social Facilitation
32.0K
Not all intergroup interactions lead to negative outcomes. Sometimes, being in a group situation can improve performance. Social facilitation occurs when an individual performs better when an audience is watching than when the individual performs the behavior alone. This typically occurs when people are performing a task for which they are skilled.
32.0K
02:55Stereotypes, Prejudice, and Discrimination
90.2K
Humans are very diverse and although we share many similarities, we also have many differences. The social groups we belong to help form our identities (Tajfel, 1974). These differences may be difficult for some people to reconcile, which may lead to prejudice toward people who are different. Prejudice is a negative attitude and feeling toward an individual based solely on one’s membership in a particular social group (Allport, 1954; Brown, 2010). Prejudice is common against people who...
90.2K
01:30Dementia
120
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
120
01:26Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
01:30Cognitive Development During Adulthood
125
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
125
01:22Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200